A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1 Diabetes
| Autor: | Stephan Matthaei, Andreas Hamann, Christoph Rosak, Louise Silvestre |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Time Factors Randomization Adolescent endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment Insulin Glargine Bedtime Drug Administration Schedule Body Mass Index law.invention Eating Randomized controlled trial law Internal medicine Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents Insulin Aged Glycated Hemoglobin Advanced and Specialized Nursing Type 1 diabetes business.industry Insulin glargine Patient Selection digestive oral and skin physiology Fasting Middle Aged medicine.disease Hypoglycemia Insulin Long-Acting Diabetes Mellitus Type 1 Endocrinology Quality of Life Female Safety business Body mass index medicine.drug |
| Zdroj: | Diabetes Care. 26:1738-1744 |
| ISSN: | 1935-5548 0149-5992 |
| DOI: | 10.2337/diacare.26.6.1738 |
| Popis: | OBJECTIVE—Insulin glargine (Lantus), a long-acting human insulin analog, provides effective glycemic control when administered at bedtime. This open-label, randomized, parallel group, multicenter study investigated whether insulin glargine is equally effective if administered before breakfast, before dinner, or at bedtime. RESEARCH DESIGN AND METHODS—Patients with type 1 diabetes on basal-bolus therapy (n = 378, 18–68 years, HbA1c 5.5–9.8%) were treated with once-daily individually titrated insulin glargine in combination with prandial insulin lispro for 24 weeks. RESULTS—Baseline characteristics were similar in the three groups (overall age 40.9 ± 11.9 years, diabetes duration 17.3 ± 11.5 years). Median total daily insulin dose was similar at baseline (0.65, 0.65, and 0.66 IU/kg for breakfast, dinner, and bedtime, respectively) and remained relatively constant over the study period; however, the insulin glargine–to–total insulin dose ratio increased more in the breakfast group than in the dinner and bedtime groups. A similar reduction of adjusted mean HbA1c from baseline to end point occurred in all patients (7.6–7.4, 7.6–7.5, and 7.6–7.5% for breakfast, dinner, and bedtime, respectively), and a similar percentage achieved HbA1c CONCLUSIONS—These data suggest that insulin glargine, in combination with insulin lispro, is safe and effective when administered before breakfast, before dinner, or at bedtime. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|